Jeff Bird

Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Xoft, Inc. develops Electronic Brachytherapy systems for radiation therapy applications. Its products include the Axxent Controller, which utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed; Axxent HDR X-ray Source, a low energy radiation treatment without the use of radioactive isotopes; Axxent Applicators, which provides a channel for the Axxent X-ray Source to deliver high dose rate, low energy radiation directly to the targeted area; and Axxent Accessories, an accessory product line designed to support and aid a physician during a procedure or treatment of cancer radiation. The company was founded by Michael Forman in 1998 and is headquartered in San Jose, CA.

AkaRx, Inc. engages in the develop and manufacture of biopharmaceutical products for applications in hematology and therapeutic treatments for clinical-stage cancer. It offers thrombocytopenia treatment avatrombopag. The company was founded by Robert E. Desjardins and Donna Tempel in 2005 and is headquartered in NJ.

ROXRO Pharma, Inc. develops hospital strength acute pain products. Its products include ROX-888, an intranasal formulation for the treatment of dental and postoperative pain; ROX-828, a non-opioid and non-triptan intranasal product for the treatment of migraine; and SPRIX nasal spray for the short-term management of acute moderate to moderately severe pain that requires analgesia at the opioid level. The company was founded by Michael E Fitzgerald, Roger Whiting and Roberto Pedro Rosenkranz in 1999 and is headquartered in Menlo Park, CA.

Naryx Pharma, Inc. developd products for the treatment of chronic sinusitis. Its products were focused on inhaled, nebulizer, intranasal drug formulations. Its products include Sybryx, which is used for the treatment of chronic sinusitis. The company focused on development of inhaled, nebulized, and intranasal drug formulations. The company was founded in 1999 and was headquartered in Carpinteria, CA.

Virobay, Inc. develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases. It utilize cysteine cathepsin platform for the development and commercialization of novel drugs. The firm's research & development activities focuses on neuropathic pain, autoimmune diseases and liver fibrosis. The company was founded by Robert F. G. Booth on May 18, 2006 and is headquartered in Menlo Park, CA.

Restoration Robotics, Inc. manufactures and develops medical devices for hair transplantation services. It provides artas system, a computer-assisted, physician-controlled system to harvest follicular units directly from the scalp. It operates in the United States, Europe and Middle East, Asia pacific, and Rest of the World. The company was founded by Mohan Bodduluri, Don Caddes, Phillip L. Gildenberg and Fredrick H. Moll on November 22, 2002 and is headquartered in San Jose, CA.

Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ.

Procyrion, Inc. manufactures medical devices. The firm develops percutaneous circulatory assist device intended to treat chronic heart failure. Its product Aortix is a catheter deployed circulatory assist device for the millions of heart failure patients who are too sick for medication alone. The company was founded by Reynolds M. Delgado III in 2005 and is headquartered in Houston, TX.

Stanford Health Care provides healthcare services. It services includes cardiac care, cancer treatment, neurosciences, surgery and organ transplants. The company was founded in 1956 and is headquartered in Stanford, CA.

Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.

Theracos, Inc. operates as a pharmaceutical research and development company. The firm supports preclinical & clinical research & development in inflammatory, metabolic and affective disorders. It specializes in all aspects of pharmaceutical development including medicinal and process chemistry, pharmacology, toxicology, pharmacokinetics, manufacturing, formulation, QA/QC, regulatory affairs and the design and execution of clinical trials. The company was founded by Edward P. Amento and is headquartered in Marlborough, MA.

Helix OpCo LLC is a genomics company. It offers consumer genetics, next generation sequencing (ngs), bioinformatics, consumer insights, big data, dna, population health, and genomics. The company was founded by Justin Kao, Scott Burke, Jay T Flatley and James Lu in 2015 and is headquartered in San Mateo, CA.

TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA.

Bluebird Ventures (Bluebird Ventures) is a venture capital firm founded in 2019 by Jeffrey Bird. The firm is headquartered in Palo Alto, California.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA.